FDMT · 4D Molecular Therapeutics, Inc.
$9.61
-0.24 (-2.44%)
At close · Jul 29
Market Cap
$681.74M
Shares
69.21M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David Kirn | CEO | $2,051,343 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David Kirn | CEO | $1,009,004 |
| Uneek Mehra | Chief Financial and Business Officer | $823,899 |
| Fariborz Kamal | COO | $734,607 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Kirn | CEO | $10,286,808 |
| Fariborz Kamal | COO | $4,544,260 |
| Robert Kim | Chief Medical Officer | $3,964,950 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Kirn | CEO | $3,287,970 |
| Fariborz Kamal | COO | $2,386,301 |
| August J. Moretti | CFO | $2,173,940 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David Kirn | CEO | $5,200,825 |
| August J. Moretti | CFO | $2,635,785 |
| Theresa Janke | Chief of Staff | $2,572,695 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Fishman | Chief Medical Officer | $3,339,803 |
| David Kirn | CEO | $701,533 |
| August J. Moretti | CFO | $632,762 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| August J. Moretti | CFO | $2,137,710 |
| David Kirn | CEO | $554,300 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kristian Humer | Principal Accounting Officer | Appointed | 2026-03-30 |
| Glenn Sblendorio | Class I director | Appointed | 2026-01-07 |
| Kristian Humer | Chief Financial Officer and Principal Financial Officer | Appointed | 2025-11-17 |
Key facts
CIK
1650648
CUSIP
35104E100
13F (30d)
22 filings
22 filers
Visit website
Investor relations